bioAffinity gets Hong Kong patent for CyPath Lung platform
bioAffinity Technologies says it received a Hong Kong patent covering its CyPath Lung platform, which uses antibodies, TCPP, and flow cytometry to assess lung cancer likelihood in sputum.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.